Concepedia

Publication | Open Access

A Phase I Dose-Escalation Study of Antibody BI-505 in Relapsed/Refractory Multiple Myeloma

DOIFull Paper Access

49

Citations

10

References

2015

Year

Markus Hansson, Peter Gimsing, Ashraf Badros, Titti Martinsson Niskanen, Hareth Nahi, Fritz Offner, Morten Salomo, Elisabeth Sonesson, Morten Mau‐Sørensen, Yvonne Stenberg,
Clinical Cancer Research

Abstract

BI-505 can be safely administered at doses that saturate myeloma cell ICAM-1 receptors in patients. This study was registered at www.clinicaltrials.gov (NCT01025206).

References

YearCitations

Page 1